Veru Inc. Charts Risky but Clearer Post-GLP-1 Path

Veru Inc ((VERU)) has held its Q1 earnings call. Read on for the main highlights of the call.

Veru Inc.’s latest earnings call struck a cautiously optimistic tone, with management highlighting positive clinical momentum, fresh regulatory clarity, and a bolstered balance sheet that together overshadow ongoing losses and funding risks. Investors were told the path forward is clearer, but success still hinges on flawless trial execution and future access to capital.

Positive Phase 2b Proof-of-Concept Results

Veru reported encouraging Phase 2b “quality” data in 168 older patients, where Novosarm added to a GLP‑1 receptor agonist produced greater fat mass loss while preserving lean mass and physical function. Importantly, patients who stopped semaglutide experienced reduced weight and fat regain when on Novosarm, addressing a major drawback of current GLP‑1 therapies.

Regulatory Clarity from Successful FDA Meeting

A key win came from a recent FDA meeting, which laid out two clear regulatory paths for Novosarm when combined with GLP‑1 drugs. Either the combo must deliver at least a 5% placebo‑corrected incremental weight loss at 52 weeks, or, with less incremental weight loss, prove meaningful gains in physical function such as Stair Climb performance.

New Validated BMD Surrogate Endpoint Opportunity

The FDA’s validation of total hip bone mineral density by DEXA as a surrogate endpoint in postmenopausal osteoporosis gives Veru a new angle. Novosarm’s preclinical anabolic and anti‑resorptive bone data could support a BMD‑based approval path for postmenopausal women on GLP‑1s, where fracture risk is a growing concern.

PLATO Phase 2b Trial Initiation and Design

Veru plans to launch the PLATO Phase 2b study this quarter, enrolling roughly 200 patients aged 65 and older with BMI of at least 35 who are starting semaglutide. The 68‑week trial will use percent change in total body weight as the primary endpoint, with a 34‑week DEXA interim analysis to assess lean and fat mass shifts.

Successful Capital Raise Strengthening Cash Position

To fund its pipeline, Veru completed an underwritten offering on Oct. 31, 2025, raising about $23.4 million in net proceeds via common stock, pre‑funded warrants, and Series A/B warrants. This transaction was framed as a critical step in securing enough runway to execute the near‑term clinical plan.

Improved Liquidity and Working Capital

The capital raise and tighter spending helped lift cash, cash equivalents, and restricted cash to $33.0 million from $15.8 million, more than doubling the company’s liquidity. Net working capital surged to $29.7 million from $11.1 million, with management saying this should fund operations through the PLATO interim analysis.

Operating Expense and Loss Improvements

Cost discipline is starting to show, as R&D spend fell to $1.3 million from $5.7 million following the wind‑down of the earlier Phase 2b trial. General and administrative expenses also declined, driving net loss down to $5.3 million from $8.9 million and nearly halving operating cash burn for the quarter.

Company Remains Unprofitable with Negative Cash Flow History

Despite these improvements, Veru remains firmly in the red and has a track record of negative operating cash flow. Management acknowledged that continued clinical development will demand additional capital beyond current milestones, especially if timelines slip or study costs escalate.

Funding Horizon Limited to Interim Analysis

The company currently expects its cash to last only through the PLATO DEXA interim analysis, projected for 2027. That means investors should anticipate another financing event to complete the full 68‑week trial and any subsequent stages, leaving equity holders exposed to potential dilution.

Regulatory Approval Pathways Conditional and Uncertain

While the FDA’s dual‑path framework is encouraging, it adds conditional risk to the story. Novosarm must either deliver strong incremental weight loss or convincingly prove functional or bone health benefits, and trial outcomes will determine which bar the program ultimately faces at registration.

Previous One-Time Gains Not Recurring

Management reminded listeners that earlier periods benefited from one‑off gains like debt extinguishment and asset sales that boosted reported results. With those tailwinds gone, investors should assess the business on its core operating trajectory rather than past nonrecurring boosts.

Clinical Landscape Challenge: GLP-1 Treatment Plateau

Veru underscored a major industry challenge: about 88% of GLP‑1 patients hit a weight‑loss plateau at one year, and most remain clinically obese at that point. This plateau, along with lean mass loss and elevated fracture risk, creates both a sizable unmet need and a high bar for Novosarm to show meaningful, differentiating benefit.

Long Timelines to Interim Readout

The company does not expect the PLATO interim DEXA readout until 2027, stretching the timeline for key value inflection. With no planned futility or sample‑size adjustment at interim, investors face prolonged exposure to development risk before seeing whether Novosarm can deliver on its promise.

Forward-Looking Guidance and Strategic Priorities

Looking ahead, Veru is steering development along the two FDA‑defined paths, targeting either incremental weight loss or robust functional and BMD outcomes as its approval anchors. The PLATO trial, including extensive secondary endpoints like Stair Climb, hip BMD, and metabolic markers, will be central to proving Novosarm’s add‑on value, while the company manages cash to reach the 2027 interim milestone.

Veru’s earnings call painted a picture of a small biotech with sharpened focus, a healthier balance sheet, and a potentially differentiated asset in a crowded GLP‑1 ecosystem. The upside from successful PLATO data and a clear approval path is meaningful, but investors must weigh that against long timelines, persistent losses, and the likelihood of future dilution.